Thai Ramp-Up And Chinese Approvals Will Boost Efficiency

Key Takeaways

• New plant operations, production improvements, and regulatory approvals position Corbion for greater operational efficiency and multi-year growth in key biobased markets.
  
• Focus on natural preservation, backward integration, and stable input costs supports sustained margin expansion and stronger free cash flow generation.
  
• Margin and earnings growth are at risk from persistent demand weakness, pricing pressures, currency volatility, and the challenges of recovering large capital investments.

Catalysts

Provides lactic acid and lactic acid derivatives, food preservation solutions, functional blends, and algae ingredients in the Netherlands, the United States, Asia, rest of North Americas, the rest of Europe, the Middle East, and Africa.

• Ramp-up of the new gypsum-free lactic acid plant in Thailand is expected to significantly boost production capacity and operating efficiency, enabling Corbion to meet rising demand for biobased chemicals and food preservation solutions, positively impacting revenue and EBITDA margins through improved scale and lower unit costs.
  
• Securing regulatory approvals in China for algae-derived omega-3 products unlocks a large, fast-growing human and animal nutrition market, presenting an opportunity for multi-year, volume-driven growth in the Health & Nutrition segment, which is expected to support sustained revenue and margin expansion.
  
• Ongoing yield and throughput improvements in omega-3 production are increasing output from existing assets without requiring major incremental CapEx, driving better operational leverage and supporting higher EBITDA margins in the coming years.
  
• Expansion and innovation in natural preservation applications (e.g., food ferments, mold inhibitors, functional foods) is well aligned with global consumer and regulatory shifts toward cleaner labels and reduced food waste, fueling mid
• to long-term revenue growth in specialty food ingredients.
  
• Backward integration initiatives (such as the new vinegar plant in Alabama and favorable long-term sugar hedges achieved at pre-COVID price levels) will reduce exposure to input cost volatility, providing more stable margins and improved free cash flow generation starting in H2 2025 and especially in 2026.

Corbion Future Earnings and Revenue Growth

Assumptions

• Analysts are assuming Corbion's revenue will grow by 1.0% annually over the next 3 years.
• Analysts assume that profit margins will increase from 5.1% today to 8.0% in 3 years time.
• Analysts expect earnings to reach €107.7 million (and earnings per share of €1.48) by about August 2028, up from €65.6 million today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as €82 million.
• In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 14.5x on those 2028 earnings, which is the same as it is today today. This future PE is lower than the current PE for the GB Chemicals industry at 15.0x.
• Analysts expect the number of shares outstanding to decline by 0.31% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 6.3%, as per the Simply Wall St company report.

Corbion Future Earnings Per Share Growth

Risks

• Prolonged weakness and volatility in the Biochemicals segment, driven by persistent demand softness (notably in semiconductors, agrochemicals, and animal feed) and increasing regulatory/formulation changes, may depress top-line growth and contribute to revenue headwinds over the medium to long term.
  
• Sustained low global PLA (polylactic acid) prices due to depressed fossil-based polymer competition and high exposure to the Chinese market could limit Corbion's ability to expand margins and generate attractive earnings in its high-growth joint venture, undermining expected returns from major capacity investments.
  
• Downward pressure on pricing, particularly in the 30% non-contracted portion of the omega-3 business exposed to commodity fish oil fluctuations, and uncertainty over the outcome of contract renegotiations for 2026, could negatively impact both revenue stability and EBITDA margins in coming years.
  
• Corbion's long-term financials are exposed to significant currency headwinds (notably U.S. dollar and Brazilian real depreciation), which recently reduced sales and EBITDA, and could persistently dampen reported revenues and net earnings if currency volatility continues.
  
• Incremental operating leverage from yield improvements and cost efficiencies may be offset by rising depreciation and interest expenses tied to heavy capital investments (e.g., the Thai lactic acid plant), and if volumes disappoint or cost savings stall, this could compress net margins and slow overall earnings growth.

Valuation

• The analysts have a consensus price target of €22.733 for Corbion based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of €31.9, and the most bearish reporting a price target of just €14.0.
  
• In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be €1.3 billion, earnings will come to €107.7 million, and it would be trading on a PE ratio of 14.5x, assuming you use a discount rate of 6.3%.
  
• Given the current share price of €16.4, the analyst price target of €22.73 is 27.9% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.